Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

OncoImmunology

Volumn 3, Issue 5, 2014, Pages

  Yoshimoto, Takayuki ^a   Mizoguchi, Izuru ^a   Katagiri, Seiichiro ^a   Tauchi, Tetsuzo ^a   Furusawa, Jun Ichi ^a   Chiba, Yukino ^a   Mizuguchi, Junichiro ^a   Ohyashiki, Junko H ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic myeloid leukemia; Cytotoxic T lymphocytes; Imatinib; Immunosurvelliance; NK cells; Predictive marker

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; PROTEIN KINASE LCK; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; PATIENT IDENTIFICATION; PREDICTION;

EID: 84904035014     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28861     Document Type: Article

References (10)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96:3343-56; PMID:11071626
2. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6; PMID:8616716; http://dx.doi.org/10.1038/nm0596-561
3. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, et al.; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11:1029-35; PMID:20965785; http://dx.doi.org/10.1016/S1470-2045(10)70233-3
4. Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 2012; 97:903-6; PMID:22180435; http://dx.doi.org/10.3324/haematol.2011.056853
5. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010; 24:1719-24; PMID:20811403; http://dx.doi.org/10.1038/leu.2010.185
6. Ohyashiki K, Katagiri S, Tauchi T, Ohyashiki JH, Maeda Y, Matsumura I, Kyo T. Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol 2012; 157:254-6; PMID:22077498; http://dx.doi.org/10.1111/j.1365-2141.2011.08939.x
7. Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y, Inokuchi K, Ohyashiki JH, Ohyashiki K. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci 2013; 104:1146-53; PMID:23758044; http://dx.doi.org/10.1111/cas.12216
8. Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, Voglová J, Sinisalo M, Flochová E, Vakkila J, et al. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 2011; 6:e23022; PMID:21857985; http://dx.doi.org/10.1371/journal.pone.0023022
9. Kijima M, Gardiol N, Held W. Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo. PLoS One 2011; 6:e27639; PMID:22132120; http://dx.doi.org/10.1371/journal.pone.0027639
10. Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S, Hehlmann R, Neubauer A, Hochhaus A. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010; 28:1429-35; PMID:20142590; http://dx.doi.org/10.1200/JCO.2009.25.5075